Medicure Inc (MCUJF) stock analysis
Close on Oct 19, 2026
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
Medicure passes 6 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 0/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
Medicure has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
Growing faster than the industry
Revenue grew 31.7% over the last twelve months; the Drugs median is 8.0%.
What to watch
Revenue growing under 10% a year
Revenue grew 7.8% a year over the last three fiscal years, short of the 10% we look for.
Gross margin slipping
Gross margin was 40.7% over the last twelve months, against 59.7% a year earlier.
No dividend
Medicure has not paid a dividend in the last twelve months.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B against the industry
Needs positive book value.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth1/6
Revenue growing under 10% a year
Revenue grew 7.8% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 31.7% over the last twelve months; the Drugs median is 8.0%.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin slipping
Gross margin was 40.7% over the last twelve months, against 59.7% a year earlier.
Past performance0/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity against the industry
Needs positive equity.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health5/6
No debt
Medicure has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 1.02 times current liabilities.
Bankruptcy risk (Altman Z)
Needs market value, working capital and retained earnings.
Dividend0/6
No dividend
Medicure has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Medicure. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
Operating margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +31.7% | +7.8% | +20.0% | +2.7% | |
| Gross profit | -10.2% | -9.9% | +18.0% | -5.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 0.90 | 1.27 | 1.02 | |
| Interest coverage | 2.6× | – | – | |
| Inventory turnover | – | 1.1× | 5.5× | |
| Diluted shares | 17M | 10M | 10M |
Cash use needs five years of cash flow figures
Medicure does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-C$560.00K
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-C$560.00K vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.89 → 1.02
- No dilutionShare count did not rise10M → 10M
- Gross margin improvedGross margin up on the prior year59.75% → 40.71%
- More efficientAsset turnover rose0.78 → 0.97
See a number that looks wrong?